Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen.
BACKGROUND
Fexofenadine, the hydrochloride salt of terfenadine active metabolite, is a nonsedative, noncardiotoxic antihistamine derivative for the treatment of allergic rhinitis.


OBJECTIVE
We sought to compare the effects of terfenadine and fexofenadine on nasal provocation tests with allergen.


METHODS
A preliminary provocation test (screening phase) was performed in 25 patients with a history of seasonal allergic rhinitis to grass pollen to determine the combined nasal reaction threshold, which was defined as 2 of the 3 following criteria: (1) at least a 40% decrease in peak nasal inspiratory flow and/or a 30% decrease in minimal cross-sectional area as measured by acoustic rhinometry, nasal secretions of 0.5 g, and 5 to 10 sneezes per minute. Patients were then included into a double-blind, randomized, 2-way crossover study to receive terfenadine or fexofenadine 120 mg 2 hours before provocation. Rhinorrhea, sneezing, peak nasal flow, and minimal nasal cross-sectional area, as well as symptom scores for nasal congestion and itchiness, were recorded at each allergen concentration up to the reaction threshold. The whole study was performed out of allergy season.


RESULTS
Fexofenadine was as potent as terfenadine in limiting pruritus and nasal congestion. Rhinorrhea and sneezing were better controlled by fexofenadine than by terfenadine. Overall, the allergen concentration necessary to reach the combined reaction threshold was increased after treatment with both drugs. Comparison between screening and each treatment phase indicated that the shift in allergen concentration to reach the reaction threshold was significantly greater after fexofenadine than after terfenadine (P =. 033).


CONCLUSIONS
After oral administration, fexofenadine provided better protection than terfenadine against the immediate allergic reaction.
Terrien
M H
MH
Division of Immunology and Allergy and ENT Service, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Rahm
F
F
Fellrath
J M
JM
Spertini
F
F
D000328:Adult; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009299:Nasal Provocation Tests; D010036:Otolaryngology / Q000379:methods; D010366:Peak Expiratory Flow Rate; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis / Q000188:drug therapy; D016593:Terfenadine / Q000031:analogs & derivatives* / Q000494:pharmacology*
D016593:Terfenadine; C093230:fexofenadine